The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation
Open accessAbstract
Gamma delta T (γδT) lymphocytes are primed for rapid function, including cytotoxicity toward cancer cells, and are a component of the immediate stress response. Following activation, they can function as professional antigen-presenting cells. Chimeric antigen receptors (CARs) work by focusing T cell function on defined cell surface tumor antigens and provide essential costimulation for robust activation. Given the natural tropism of γδT cells for the tumor microenvironment, we hypothesized that their transduction with CARs might enhance cytotoxicity while retaining their ability to migrate to tumor and act as antigen-presenting cells to prolong the intratumoral immune response. Using a GD2-targeting CAR as a model system, we showed that γδT cells of both Vδ1 and Vδ2 subsets could be expanded and transduced to sufficient numbers for clinical studies. The CAR added to the cells' innate cytotoxicity by enhancing GD2-specific killing of GD2-expressing cancer cell lines. Migration toward tumor cells in vitro was not impaired by the presence of the CAR. Expanded CAR-transduced Vδ2 cells retained the ability to take up tumor antigens and cross presented the processed peptide to responder alpha beta T (αβT) lymphocytes. γδ CAR-T cell products show promise for evaluation in clinical studies of solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
The prognostic landscape of genes and infiltrating immune cells across human cancers
Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3909 · Cited by 3,118
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
The Basic Principles of Chimeric Antigen Receptor Design
Sadelain, M., Brentjens, R., & Rivière, I. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0548 · Cited by 1,535
Six-of-the-best: unique contributions of γδ T cells to immunology
Vantourout, P., & Hayday, A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3384 · Cited by 1,232
Kawalekar, O. U., O’Connor, R. S., Fraietta, J. A., Guo, L., McGettigan, S. E., Posey, A. D., Patel, P. R., Guedan, S., Scholler, J., Keith, B., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.021 · Cited by 1,230
Pule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195
Louis, C. U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G. D., Rossig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,163
γδ T cell effector functions: a blend of innate programming and acquired plasticity
Bonneville, M., O'Brien, R. L., & Born, W. K. (2010) · Nature Reviews Immunology · doi:10.1038/nri2781 · Cited by 952
Zhao, Z., Condomines, M., van der Stegen, S. J. C., Perna, F., Kloss, C. C., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.004 · Cited by 843
Geginat, J., Lanzavecchia, A., & Sallusto, F. (2003) · Blood · doi:10.1182/blood-2002-11-3577 · Cited by 601
Dieli, F., Vermijlen, D., Fulfaro, F., Caccamo, N., Meraviglia, S., Cicero, G., Roberts, A., Buccheri, S., D'Asaro, M., Gebbia, N., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0199 · Cited by 497
Pulè, M. A., Straathof, K. C., Dotti, G., Heslop, H. E., Rooney, C. M., & Brenner, M. K. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.016 · Cited by 487
A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy
Philip, B., Kokalaki, E., Mekkaoui, L., Thomas, S., Straathof, K., Flutter, B., Marin, V., Marafioti, T., Chakraverty, R., Linch, D., et al. (2014) · Blood · doi:10.1182/blood-2014-01-545020 · Cited by 397
Self-citationJohnson, L. A., Heemskerk, B., Powell, D. J., Cohen, C. J., Morgan, R. A., Dudley, M. E., Robbins, P. F., & Rosenberg, S. A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.9.6548 · Cited by 343
Dieli, F., Poccia, F., Lipp, M., Sireci, G., Caccamo, N., Di Sano, C., & Salerno, A. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030235 · Cited by 322
Heczey, A., Liu, D., Tian, G., Courtney, A. N., Wei, J., Marinova, E., Gao, X., Guo, L., Yvon, E., Hicks, J., et al. (2014) · Blood · doi:10.1182/blood-2013-11-541235 · Cited by 318
Cross-presenting human γδ T cells induce robust CD8 + αβ T cell responses
Brandes, M., Willimann, K., Bioley, G., Lévy, N., Eberl, M., Luo, M., Tampé, R., Lévy, F., Romero, P., & Moser, B. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810059106 · Cited by 277
Bennouna, J., Bompas, E., Neidhardt, E. M., Rolland, F., Philip, I., Galéa, C., Salot, S., Saiagh, S., Audrain, M., Rimbert, M., et al. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0491-8 · Cited by 249
Almeida, A. R., Correia, D. V., Fernandes-Platzgummer, A., da Silva, C. L., da Silva, M. G., Anjos, D. R., & Silva-Santos, B. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0597 · Cited by 229
Human Vγ9Vδ2 T cells: promising new leads for immunotherapy of infections and tumors
Bonneville, M., & Scotet, E. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.07.002 · Cited by 203
Deniger, D. C., Switzer, K., Mi, T., Maiti, S., Hurton, L., Singh, H., Huls, H., Olivares, S., Lee, D. A., Champlin, R. E., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.267 · Cited by 184
γδ T cells for cancer immunotherapy: A systematic review of clinical trials
Fisher, J. P., Heuijerjans, J., Yan, M., Gustafsson, K., & Anderson, J. (2014) · OncoImmunology · doi:10.4161/onci.27572 · Cited by 177
Self-citationAbe, Y., Muto, M., Nieda, M., Nakagawa, Y., Nicol, A., Kaneko, T., Goto, S., Yokokawa, K., & Suzuki, K. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.04.008 · Cited by 176
Ontogeny of γδ T Cells in Humans
De Rosa, S. C., Andrus, J. P., Perfetto, S. P., Mantovani, J. J., Herzenberg, L. A., Herzenberg, L. A., & Roederer, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.3.1637 · Cited by 174
Characterization of Tumor Reactivity of Human Vγ9Vδ2 γδ T Cells In Vitro and in SCID Mice In Vivo
Kabelitz, D., Wesch, D., Pitters, E., & Zöller, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.11.6767 · Cited by 163
Himoudi, N., Morgenstern, D. A., Yan, M., Vernay, B., Saraiva, L., Wu, Y., Cohen, C. J., Gustafsson, K. T., & Anderson, J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102654 · Cited by 145
Self-citationHuman γδ T cells as mediators of chimaeric‐receptor redirected anti‐tumour immunity
Rischer, M., Pscherer, S., Duwe, S. C., Vormoor, J. H., Jürgens, H., & Rössig, C. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05077.x · Cited by 134
Gomes, A. Q., Martins, D., & Silva‐Santos, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-3236 · Cited by 134
Fisher, J. P. H., Yan, M., Heuijerjans, J., Carter, L., Abolhassani, A., Frosch, J., Wallace, R., Flutter, B. R., Capsomidis, A., Hubank, M. J. F., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3464 · Cited by 119
Self-citationSiegers, G. M., Dhamko, H., Wang, X.-H., Mathieson, A. M., Kosaka, Y., Felizardo, T. C., Medin, J. A., Tohda, S., Schüler, J. B., Fisch, P., et al. (2011) · Cytotherapy · doi:10.3109/14653249.2011.553595 · Cited by 98
Siegers, G. M., & Lamb, L. S. (2014) · Molecular Therapy · doi:10.1038/mt.2014.104 · Cited by 97
Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
Kondo, M., Izumi, T., Fujieda, N., Kondo, A., Morishita, T., Matsushita, H., & Kakimi, K. (2011) · Journal of Visualized Experiments · doi:10.3791/3182 · Cited by 93
The Evolution of T-cell Therapies for Solid Malignancies
Fousek, K., & Ahmed, N. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2675 · Cited by 91
Beatty, G. L., & Moon, E. K. (2014) · OncoImmunology · doi:10.4161/21624011.2014.970027 · Cited by 85
Thomas, S., Straathof, K. C. M., Himoudi, N., Anderson, J., & Pulè, M. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152196 · Cited by 66
Self-citationγδ T Cells in Cancer Immunotherapy: Current Status and Future Prospects
Chiplunkar, S. V., Dhar, S., Wesch, D., & Kabelitz, D. (2009) · Immunotherapy · doi:10.2217/imt.09.27 · Cited by 58
Siegers, G. M., Ribot, E. J., Keating, A., & Foster, P. J. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1353-y · Cited by 56
Carlo, E. D., Bocca, P., Emionite, L., Cilli, M., Cipollone, G., Morandi, F., Raffaghello, L., Pistoia, V., & Prigione, I. (2013) · Molecular Therapy · doi:10.1038/mt.2013.38 · Cited by 52
Expanded Human Blood-Derived γδT Cells Display Potent Antigen-Presentation Functions
Khan, M. W. A., Curbishley, S. M., Chen, H., Thomas, A. D., Pircher, H., Mavilio, D., Steven, N. M., Eberl, M., & Moser, B. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00344 · Cited by 51
Schilbach, K., Frommer, K., Meier, S., Handgretinger, R., & Eyrich, M. K. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31818955ad · Cited by 38
Barisa, M., Kramer, A. M., Majani, Y., MOULDING, D. A., Saraiva, L., Bajaj‐Elliott, M., Anderson, J., & Gustafsson, K. T. (2017) · Scientific Reports · doi:10.1038/s41598-017-02886-8 · Cited by 31
Self-citation
Cited by
‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
Depil, S., Duchateau, P., Grupp, S. A., Mufti, G., & Poirot, L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0051-2 · Cited by 1,227
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852
Macrophage-Based Approaches for Cancer Immunotherapy
Anderson, N. R., Minutolo, N. G., Gill, S., & Klichinsky, M. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2990 · Cited by 698
The Emerging Landscape of Immune Cell Therapies
Weber, E. W., Maus, M. V., & Mackall, C. L. (2020) · Cell · doi:10.1016/j.cell.2020.03.001 · Cited by 446
Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies
Sebestyen, Z., Prinz, I., Déchanet-Merville, J., Silva-Santos, B., & Kuball, J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0038-z · Cited by 425
Metadata
- Authors
- Capsomidis, A., Benthall, G., Van Acker, H. H., Fisher, J., Kramer, A. M., Abeln, Z., Majani, Y., Gileadi, T., Wallace, R., Gustafsson, K., Flutter, B., & Anderson, J.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 26
- Issue
- 2
- Pages
- 354-365
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2775161773
- Cited by
- 274
- References
- 42
- FWCI
- 6.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.